Eurofins Scientific SE (ERFSF)
66.35
+0.85
(+1.30%)
USD |
OTCM |
Dec 10, 14:32
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.79B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 29.81% |
| Valuation | |
| PE Ratio | 26.90 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.632 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.6810 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 67.69% |
Profile
| Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg. |
| URL | http://www.eurofins.com |
| Investor Relations URL | https://www.eurofins.com/investors |
| HQ State/Province | Luxembourg |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 29, 2026 (est.) |
| Last Earnings Release | Jul. 23, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |
Ratings
Profile
| Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg. |
| URL | http://www.eurofins.com |
| Investor Relations URL | https://www.eurofins.com/investors |
| HQ State/Province | Luxembourg |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 29, 2026 (est.) |
| Last Earnings Release | Jul. 23, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |